Why Aimmune Therapeutics Shares Fell 23.3% in February
Shares of Aimmune Therapeutics (NASDAQ: AIMT) fell 23.3% in February, according to data provided by S&P Global Market Intelligence, as the launch of its new peanut allergy treatment took time to unfold.
Aimmune rose 40% last year as investors anticipated Palforzia, the first treatment approved by the Food and Drug Administration for peanut allergy in children. The regulatory agency approved the treatment on Jan. 31, and now investors are waiting to see how the first weeks of sales progress. The process is taking time because of the risk management procedure involved in the launch.
Image source: Getty Images.
Source Fool.com